Breast surgery after neoadjuvant chemotherapy: time for a change?

Philip M Spanheimer¹, Katherine E Reeder-Hayes²

Affiliations

¹ Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7213, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7213, USA. Electronic address: philip_spanheimer@med.unc.edu.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7213, USA; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7213, USA.

PMID: 36306811
DOI: 10.1016/S1470-2045(22)00649-0

Comment

Breast surgery after neoadjuvant chemotherapy: time for a change?

Philip M Spanheimer et al. Lancet Oncol. 2022 Dec.

. 2022 Dec;23(12):1477-1479.

doi: 10.1016/S1470-2045(22)00649-0. Epub 2022 Oct 25.

Authors

Philip M Spanheimer¹, Katherine E Reeder-Hayes²

Affiliations

¹ Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7213, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7213, USA. Electronic address: philip_spanheimer@med.unc.edu.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7213, USA; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7213, USA.

PMID: 36306811
DOI: 10.1016/S1470-2045(22)00649-0

No abstract available

PubMed Disclaimer

Conflict of interest statement

PMS reports grant funding from Pfizer paid to their institution. KER-H reports grant funding from Pfizer paid to their institution.

Comment on

Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM; Exceptional Responders Clinical Trials Group. Kuerer HM, et al. Lancet Oncol. 2022 Dec;23(12):1517-1524. doi: 10.1016/S1470-2045(22)00613-1. Epub 2022 Oct 25. Lancet Oncol. 2022. PMID: 36306810 Clinical Trial.

Cited by

Cross-modal deep learning model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer.
Guo J, Chen B, Cao H, Dai Q, Qin L, Zhang J, Zhang Y, Zhang H, Sui Y, Chen T, Yang D, Gong X, Li D. Guo J, et al. NPJ Precis Oncol. 2024 Sep 5;8(1):189. doi: 10.1038/s41698-024-00678-8. NPJ Precis Oncol. 2024. PMID: 39237596 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Breast surgery after neoadjuvant chemotherapy: time for a change?

Affiliations

Breast surgery after neoadjuvant chemotherapy: time for a change?

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical